Aurinia Pharmaceuticals Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Aurinia Pharmaceuticals Inc. (AUPH) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $8.75 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-06
- Aurinia Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $8.35, a 68.69% increase year-over-year.
- Aurinia Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $4.95, a 7.14% increase year-over-year.
- Aurinia Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $4.62, a 15.07% decline year-over-year.
- Aurinia Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $5.44, a 22.51% decline year-over-year.
- Aurinia Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $5.09, a 18.10% increase from fiscal 2024.
- Aurinia Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $4.31, a 26.45% decline from fiscal 2023.
- Aurinia Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $5.86, a 10.12% decline from fiscal 2022.
- Aurinia Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $6.52, a 11.17% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.75 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $8.35 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $5.09 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $5.03 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | $4.98 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | $4.95 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | $4.31 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $3.82 10-Q · filed 2025-11-04 | |||
| 2024-06-30 | $3.90 10-Q · filed 2025-07-31 | |||
| 2024-03-31 | $4.62 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $5.86 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $5.94 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | $5.99 10-Q · filed 2024-08-01 | |||
| 2023-03-31 | $5.44 10-Q · filed 2024-05-02 | |||
| 2022-12-31 | $6.52 10-K · filed 2025-02-27 | |||
| 2022-09-30 | $6.60 10-Q · filed 2023-11-02 | |||
| 2022-06-30 | $7.00 10-Q · filed 2023-08-03 | |||
| 2022-03-31 | $7.02 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | $7.34 10-K · filed 2024-02-15 | |||
| 2021-09-30 | $6.64 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | $6.59 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | $6.72 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $5.58 10-K · filed 2023-02-28 | |||
| 2020-09-30 | $5.05 10-Q · filed 2021-11-03 | |||
| 2020-06-30 | $5.20 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | $5.44 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | $2.56 10-K · filed 2022-02-28 | |||
| 2018-12-31 | $2.33 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |